09 May 2018 Research

Sharing this exciting news: a treatment advance for childhood leukaemia

A deal has been struck to let the NHS offer children an expensive new cancer therapy that has been called the most exciting treatment advance for decades.

“We are excited at this breakthrough in the treatment for childhood leukaemia. CAR-T cell therapy gives those children who do not respond to chemotherapy treatment a real chance of a long-term cure. We welcome this significant step forward which will give hope to families whose children are affected by leukaemia.” 

Dr Maria Gilleece, Director, Yorkshire Blood and Marrow Transplant Programme and a member of the Leukaemia UK Medical Panel.

Follow this link to read this BBC news story.

Related posts

Nick Boles’ Ambulatory Care Unit opening speech

15 June 2018

Nick Boles’ Ambulatory Care Unit opening speech

An edited extract of the speech Nick Boles MP made at the official opening of the Leukaemia UK Ambulatory Care Unit.

Pedalling pair’s crazy peaks challenge to stop leukaemia cutting short the lives of beloved mums

1 August 2022

Pedalling pair’s crazy peaks challenge to stop leukaemia cutting short the lives of beloved mums

Leukaemia UK supporter, Alistair, who lost is mum to leukaemia less than a year ago, is setting out on an extreme fundraising challenge. Alistair, who is from Lincoln, and his…

Inquiry highlights the impact of COVID-19 on blood cancer services

11 March 2022

Inquiry highlights the impact of COVID-19 on blood cancer services

A new report has recently been published, following an inquiry by the All-Party Parliamentary Group (APPG) on Blood Cancer and the APPG on Stem Cell Transplantation and Advanced Cellular Therapies, on the impact of Covid-19 on blood cancer services in the UK.

£200 grants for people affected by leukaemia once again available

4 April 2023

£200 grants for people affected by leukaemia once again available

Leukaemia UK and Leukaemia Care have this month relaunched the ‘Cost of Living Fund’, providing financial grants of £200 to patients with leukaemia, myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPNs),…